Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback